Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis

Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis

Abstract Background Despite improvement in the overall survival of patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation, the effects of EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment on bone metastasis remain unclear. This study investigate...

Full description

Bibliographic Details
Main Authors: Michihito Miyagi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Toshiaki Takahashi, Haruyasu Murakami, Hideyuki Harada, Keita Mori, Mitsuru Takahashi
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Pulmonary Medicine
Subjects:
Bone metastases
Non-small cell lung cancer (NSCLC)
Osteosclerosis
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)
Online Access:https://doi.org/10.1186/s12890-022-02226-1

Internet

https://doi.org/10.1186/s12890-022-02226-1

Similar Items